The present invention relates to a new type of microcapsules for stabilisation of active principles, of application in the field of cosmetics, pharmaceutics or food products, as well as to its method of preparation.
According to the context of the invention, the term microcapsules may encompass the following terms: microparticles, millispheres, microspheres. However, for the purposes of this invention and in order to facilitate its comprehension the term microcapsules shall be employed.
A point of growing interest in the world of cosmetics, pharmaceutics and food is the use in cosmetics, pharmaceutics and food or diet products of substances with several nutritional, pharmaceutical properties o which can cause physiological reactions (such as cholesterol reducers, relaxants, stimulants, antioxidants, vitamin supply, enzyme supply, etc.). However, use of these substances dissolved freely within the product volume may bring about strange flavours or odours which are hard to mask, or the instability and degradation of the substance.
The inclusion or not of these substances within microcapsules can help to deal with these disadvantages. Said solution has been widely employed in the pharmaceutical and cosmetic fields, using millicapsules of amylose (WO 89/11269), millicapsules of glycolic acid (EP 0202159), microcapsules of gelatine and alginic acid (WO 87/01587), microcapsules of ateloglycanes (WO 92/02254), millicapsules of calcium alginate (EP 0391803).
Research has discovered that products of interest in the cosmetics, pharmaceutics and food fields can be advantageously encapsulated inside microcapsules consisting of a nucleus of an adsorbent material and a coating of polymeric material. Products encapsulated in this type of microcapsules show a high stability to degradation agents, regardless of whether the environment of the microcapsules is aqueous, oily or emulsion.
The object of the present invention is thus a cosmetic, pharmaceutical and food preparation to incorporate active principles of interest to cosmetics, pharmaceutics and food products, characterised in that the product of interest is encapsulated within microcapsules comprising a nucleus of an adsorbent material and a polymeric material coating.
The present invention comprises the preparation and use of microcapsules of size smaller than 500 μm, formed of an adsorbent material nucleus in which is incorporated the active substance or product of interest, covered by a polymeric material membrane.
Incorporation of the active product in the nucleus of microcapsules is performed in the following manner:
- a) Solution of the product to be encapsulated in a suitable solvent (water, ethanol, . . . );
- b) Incorporation of the product to be encapsulated in the adsorbent material by wetting the adsorbent material with the solution obtained from the previous step;
- c) Drying the adsorbent material nucleus obtained in the previous step by conventional processes in order to eliminate the solvent; and
- d) Coating the nucleus of adsorbent material incorporating the encapsulated product with a solution of polymeric material.
By adsorbent material is meant all materials of natural or synthetic origin insoluble in water which may incorporate product inside the pores of its particles. More specifically, the following products are seen as adsorbent materials:
- Natural or modified polysaccharides insoluble in water (specifically starch, agarose, cellulose, modified celluloses and their mixtures).
- Inorganic adsorbent materials (more specifically talcum, silica, diatomite earth, active carbon and their mixtures).
Polymeric coating materials are such as the following materials:
- Natural or modified natural polymers which may form films by evaporation of their solutions, such as ethylcellulose, hydroxypropylmethyl cellulose, cellulose acetylphtalate, cellulose hydroxypropylmethylphtalate and the like;
- Synthetic polymers suitable for use in cosmetics, pharmaceutics or foods which may form films by evaporation of their solutions, such as methacrylic acid polymers (Eudragit L and S), copolymers of dimethylaminoethylmetacrylate (Eudragit E), copolymers of trimethylamonioethylmetacrylate (Eudragit RL and RS) and their mixtures, polymers and copolymers of lactic and glycolic acids and their mixtures.
Compounds of interest in the fields of cosmetics, pharmaceutics and food products which may be incorporated to the preparation object of this invention include but are not limited to the following:
- Bactericide drugs such as gentamicine;
- Antiviral agents such as riphampacine or acyclovir;
- Fungicidal agents such as anphotericine B, myconazol, terconazol, econazol, isoconazol, thioconazol, biphonazol, chlotrimazol, ketoconazol, butaconazol, itraconazol, oxyconazol, phenticonazol, nystatin, naphtifine, zinoconazol, cyclopyroxolamine;
- Antiparasite compounds such as those derived from antimony;
- Antitumoral and antineoplasic compounds such as adriamycine, vinblastine, vincristine, mitomycine C, doxorubicine, daunorubicine, methotrexate, cysplatinum and others;
- Antimetabolytes;
- Proteins such as albumin;
- Toxins such as diphtheric toxin;
- Enzymes such as catalase;
- Peptides such as cyclosporine A, hirudine, somatostatin or thymopentin;
- Hormones such as oestrogen;
- Peptidic hormones such as human growth hormone, porcine growth hormone, bovine growth hormone, human calcitonin, salmon calcitonin, carbocalcitonin and insulin;
- Hormone antagonists;
- Neurotransmitters such as acetylcholine;
- Neurotransmitter antagonists;
- Glycoproteins such as hyaluronic acid;
- Lipoproteins such as alpha-lipoprotein;
- Immunoglobulins such as IgG;
- Immunomodulators such as interferon or interleukin;
- Vasodilators;
- Colorants such as Arsenaze III;
- Radioactive markers such as 14C;
- Radio opaque compounds such as 90Te;
- Fluorescent compounds such as carboxyfluorescine;
- Cell receptors such as the oestrogen receptor protein;
- Non-steroid anti-inflammatories such as indomethacine, ibuprofen, sulindac, pyroxicam and naproxen;
- Anti-inflammatories such as dexametasone;
- Anti glaucoma agents such as pilocarpin or thymolol;
- Mydriatic compounds;
- Local anaesthetics such as lidocaine;
- Narcotics such as codeine;
- Vitamins such as alpha-tocopherol;
- Nucleic acids such as thiamine;
- Polynucleotides such as RNA;
- Psychoactive or ansiolitic compounds such as diazepam;
- Mono-, di- and polysaccharides such as glycogen;
- Glycosaminoglycanes such as non fractioned heparins, low molecular mass heparins, pentasaccharide, derinatan sulphate, heparan sulphate, chondroitin-4-sulphate, chondroitin-6-sulphate and their derivatives;
- Cardiovascular agents such as alpha blockers, beta blockers, calcium, channel blockers, ACE inhibitors;
- Prostaglandins;
- Vegetable oils such as vine oil, borage oil, castor oil, olive oil, sunflower oil, and the like;
- Animal oils such as cod liver oil, fish oils, EPA-18, DHA-22 and the like;
- Cosmetic use silicones;
- Vegetable extracts such as those of ging-seng, arnica, calendula, and the like;
- Enzymes and co-enzymes such as ubidecarenone and the like;
- Animal extracts;
- Yeasts such as selenium yeast, beer yeast and the like;
- Vitamins and their derivatives such as vitamin E, vitamin E acetate, vitamin A palmitate, and the like;
- Amino acids such as cystine and the like;
- Animal proteins such as ovoalbumin, gelatine and the like,
- Vegetable proteins such as gluten and the like;
- Hydrolysed animal or vegetable proteins such as hydrolysed collagen or hydrolysed wheat gluten and the like;
- Natural polysaccharides such as hyaluronic acid and the like;
- Natural tocopherols and their mixtures such as Lipatra 2050 and the like;
- Stimulants such as caffeine and the like;
- Mineral and trace element salts, such as iron salts, zinc salts, selenium salts and the like;
- Colorants accepted in the field of cosmetics, dermopharmaceutics or food.
Microcapsules of the above described preparation may be used in:
- cosmetic products such as gels, creams, lotions, emulsions, bath gels, shampoos;
- pharmaceutical and veterinary products by topical, oral or parenteral intake;
- products meant for human or animal consumption and diet products.
Below are presented several examples of preferred embodiments of the present invention:
EXAMPLE 1
Obtaining Microcapsules Containing Docosahexenoic Acid (DHA)
In a suitable container are dissolved 5 g of DHA in 10 mL CH2Cl2; the resulting solution is added shaken onto 95 g of corn starch. Later the solvents are eliminated to obtain a starch powder containing DHA.
3 g of ethylcellulose are dissolved in 25 mL of ethanol, and the resulting solution is added in five different fractions to starch powder containing DHA previously prepared, as follows:
- 1) Addition of aliquot of ethylcellulose solution on the starch powder;
- 2) Shaking for ten minutes to obtain a homogenous system;
- 3) Drying the resulting product;
4) Repetition of step 1 until the entire ethylcellulose solution is used.
|
|
Adsorbent
Example no.Active materialmaterialCoating material
|
|
2RetinolCorn starchEthylcellulose
(Vitamin A)
3Ascorbic acidTalcumEthylcellulose
4Beta-caroteneMicrocrystallineEudragit S
cellulose
5PancreatinTalcumCellulose
acetophtalate
6UbidecarenoneDiatomite earthLactic-co-glycolic
polymer, molecular
mass 50000 and
lactic glycolic ratio
1:1
7LipaseCorn starchEthylcellulose
8Salicylic acidCorn starchEthylcellulose
9Hydrolysed wheatTalcumCellulose
protein (Pronalenacetophtalate
Flash tense)
10HydroglycolicCorn starchEthylcellulose
extract of fruits
(Pronalen Bio
protect)
11Piperite mintMicrocrystallineEthylcellulose
essencecellulose
12PerfumeCorn starchEthylcellulose
|
Patent Application
20060051408
